Rachel K. Lim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rachel K. Lim has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Adithya Cattamanchi
Affiliation Curry International Tuberculosis Center and Division of Pulmonary and Critical Care Medicine, University of California San Francisco, San Francisco, California, United States of America
1 shared publicationAlain Tremblay
Department of Medicine, University of Calgary, Calgary, Canada
1 shared publication- Alexander K. C. Leung
Cumming School of Medicine, University of Calgary
1 shared publication - Anabel Selemon
Department of Epidemiology, Biostatistics, and Occupational Health, McGill University , Montreal, Quebec
1 shared publication - Andrea S. Gershon
Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada
1 shared publication - Andréanne Côté
Division of Respiratory Medicine, Department of Medicine, IUCPQ-UL Department of Medicine, Université Laval
1 shared publication
Latest Publications
- Open Access
- 21 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Safety of Tuberculosis Preventive Treatment Among People Receiving or About to Initiate Immunosuppressive Medications: A Systematic Review and Meta-analysis
Background: People receiving immunosuppressive medications are at increased risk of tuberculosis. Tuberculosis preventive treatment (TPT) can reduce risk; however, its safety among these populations is uncertain. We conducted a meta-analysis to evaluate adverse events (AEs) associated with TPT among people receiving or about to initiate immunosuppressive medications. Methods: We searched Medline, Cochrane, Health Star, and Embase (1952–1 May 2025), for studies reporting AEs during TPT among people receiving or about to initiate immunosuppressive medications. We used random-effects generalized linear mixed models with Hartung–Knapp 95% confidence intervals (CIs) to estimate our primary outcome: pooled proportion of AE-related discontinuation, stratified by TPT regimen. Results: We included 27 studies (3184 participants). Populations included biologics/steroids recipients and solid organ/hematopoietic transplant candidates/recipients. For the primary outcome (25 studies, 2802 participants), TPT regimens included 6- to 12-month mono-isoniazid regimens (1511 participants), 4-month mono-rifamycin regimens (228 participants), 3-month isoniazid-rifamycin combination regimens (990 participants), and 6- to 9-month fluoroquinolone-based regimens (73 participants). Only mono-isoniazid regimens were provided while receiving immunosuppressive medications. Pooled AE-related discontinuation was 5.3% (95% CI, 3.1%–8.9%; I2 = 65.4%) for mono-isoniazid regimens, 4.4% (95% CI, .1%–75.4%; I2 = 86.3%) for mono-rifamycin regimens, 2.0% (1.0%–4.1%; I2 = 0.0%) for isoniazid-rifamycin combination regimens, and 6.9% (95% CI, 0–92.3%; I2 = 65.4%) for fluoroquinolone-based regimens. Proportions were similar when stratified by biologics/steroids and transplant populations. Conclusions: Overall, AE-related TPT discontinuation was similar to that in the broader TPT literature. AE-related discontinuation of TPT was lowest with rifamycin-containing regimens, but these were only provided prior to initiating immunosuppressive medications. Data on the safety of non-isoniazid regimens among people receiving immunosuppressive medications are needed.
- 21 September 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
Open AccessSafety of Tuberculosis Preventive Treatment Among People Receiving or About to Initiate Immunosuppressive Medications: A Systematic Review and Meta-analysis
Background: People receiving immunosuppressive medications are at increased risk of tuberculosis. Tuberculosis preventive treatment (TPT) can reduce risk; however, its safety among these populations is uncertain. We conducted a meta-analysis to evaluate adverse events (AEs) associated with TPT among people receiving or about to initiate immunosuppressive medications. Methods: We searched Medline, Cochrane, Health Star, and Embase (1952–1 May 2025), for studies reporting AEs during TPT among people receiving or about to initiate immunosuppressive medications. We used random-effects generalized linear mixed models with Hartung–Knapp 95% confidence intervals (CIs) to estimate our primary outcome: pooled proportion of AE-related discontinuation, stratified by TPT regimen. Results: We included 27 studies (3184 participants). Populations included biologics/steroids recipients and solid organ/hematopoietic transplant candidates/recipients. For the primary outcome (25 studies, 2802 participants), TPT regimens included 6- to 12-month mono-isoniazid regimens (1511 participants), 4-month mono-rifamycin regimens (228 participants), 3-month isoniazid-rifamycin combination regimens (990 participants), and 6- to 9-month fluoroquinolone-based regimens (73 participants). Only mono-isoniazid regimens were provided while receiving immunosuppressive medications. Pooled AE-related discontinuation was 5.3% (95% CI, 3.1%–8.9%; I2 = 65.4%) for mono-isoniazid regimens, 4.4% (95% CI, .1%–75.4%; I2 = 86.3%) for mono-rifamycin regimens, 2.0% (1.0%–4.1%; I2 = 0.0%) for isoniazid-rifamycin combination regimens, and 6.9% (95% CI, 0–92.3%; I2 = 65.4%) for fluoroquinolone-based regimens. Proportions were similar when stratified by biologics/steroids and transplant populations. Conclusions: Overall, AE-related TPT discontinuation was similar to that in the broader TPT literature. AE-related discontinuation of TPT was lowest with rifamycin-containing regimens, but these were only provided prior to initiating immunosuppressive medications. Data on the safety of non-isoniazid regimens among people receiving immunosuppressive medications are needed.
- 13 July 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (9) , 885-893
The impact on airborne isolation duration utilizing GeneXpert versus acid-fast bacilli smears to guide discontinuation among individuals with suspected pulmonary tuberculosis: a systematic review and meta-analysis
Objective: The GeneXpert® MTB/RIF nucleic acid amplification test has been proposed as an alternative method to smear microscopy in guiding de-isolation for patients with suspected pulmonary tuberculosis, given its convenience and higher diagnostic accuracy. Currently, there is no comprehensive review summarizing the evidence on the isolation duration using GeneXpert. This systematic review and meta-analysis addressed the length of airborne infection isolation in hospitalized patients initially suspected of having pulmonary tuberculosis where de-isolation decisions were guided by GeneXpert nucleic acid amplification test compared to traditional smear microscopy. Methods: We conducted a comprehensive search in databases (Medline, Embase, and Scopus) from January 1, 2001, to April 1, 2026, and applied median-based quantile estimation methods to determine the pooled difference in median times of isolation. We also assessed diagnostic accuracy as well as hospital length of stay as secondary outcomes. Results: We screened 746 titles and abstracts, of which 7 were eligible for inclusion. Five studies included in the meta-analysis involved 1,409 patients, all within low-incidence tuberculosis settings. The meta-analysis demonstrated that use of a single unconcentrated GeneXpert versus serial acid-fast bacilli smear microscopy resulted in a pooled reduction in median isolation duration by 38.8 hours (95% confidence interval 20.2–57.3 hours). Conclusion: Compared to serial microscopy, GeneXpert done on a single unconcentrated respiratory specimen reduces airborne infection isolation duration by over 1.5 days, on average, making it an attractive strategy for optimizing healthcare facility resources while evaluating persons for pulmonary tuberculosis. Protocol Registration (PROSPERO, CRD42024538644)
- 13 July 2026
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 47 (9) , 885-893
The impact on airborne isolation duration utilizing GeneXpert versus acid-fast bacilli smears to guide discontinuation among individuals with suspected pulmonary tuberculosis: a systematic review and meta-analysis
Objective: The GeneXpert® MTB/RIF nucleic acid amplification test has been proposed as an alternative method to smear microscopy in guiding de-isolation for patients with suspected pulmonary tuberculosis, given its convenience and higher diagnostic accuracy. Currently, there is no comprehensive review summarizing the evidence on the isolation duration using GeneXpert. This systematic review and meta-analysis addressed the length of airborne infection isolation in hospitalized patients initially suspected of having pulmonary tuberculosis where de-isolation decisions were guided by GeneXpert nucleic acid amplification test compared to traditional smear microscopy. Methods: We conducted a comprehensive search in databases (Medline, Embase, and Scopus) from January 1, 2001, to April 1, 2026, and applied median-based quantile estimation methods to determine the pooled difference in median times of isolation. We also assessed diagnostic accuracy as well as hospital length of stay as secondary outcomes. Results: We screened 746 titles and abstracts, of which 7 were eligible for inclusion. Five studies included in the meta-analysis involved 1,409 patients, all within low-incidence tuberculosis settings. The meta-analysis demonstrated that use of a single unconcentrated GeneXpert versus serial acid-fast bacilli smear microscopy resulted in a pooled reduction in median isolation duration by 38.8 hours (95% confidence interval 20.2–57.3 hours). Conclusion: Compared to serial microscopy, GeneXpert done on a single unconcentrated respiratory specimen reduces airborne infection isolation duration by over 1.5 days, on average, making it an attractive strategy for optimizing healthcare facility resources while evaluating persons for pulmonary tuberculosis. Protocol Registration (PROSPERO, CRD42024538644)
- Open Access
- 21 October 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (10) , e71367
Individually Tailored Physiotherapy in Persons With Respiratory Symptoms Related to Post‐Acute Sequelae of COVID‐19: A Feasibility Study With Mixed Methods
Background and Aims: Post‐acute sequelae of COVID‐19 (PASC) commonly present with persistent respiratory symptoms, even in individuals with normal chest imaging and pulmonary function. Given the heterogeneity within this population, a personalized approach to respiratory physiotherapy could improve outcomes. The purpose of this study was to assess the feasibility and impact of a tailored respiratory physiotherapy program on health‐related quality of life (QoL), functional impairment, and patient‐reported outcome measures (PROMs) in individuals with persistent respiratory symptoms due to PASC. Methods: A single‐arm, open‐label trial was conducted with 13 adults diagnosed with PASC, recruited from Long COVID clinics in Calgary, Canada. Participants underwent an 8‐session personalized physiotherapy program, including education, breathing exercises, and strengthening. Feasibility was measured through recruitment, retention, and session completion rates. PROMs were collected at baseline and post‐intervention, and qualitative interviews explored participant perspectives. Results: The program was highly feasible, with 100% retention and a 99% completion rate. Significant improvements were observed in QoL, functional status (Post COVID‐19 Function Status scale), and self‐efficacy scores. The 6‐min walk test showed clinically meaningful improvements in three out of seven participants. Qualitative interviews ( n = 8) identified three main themes: struggles with PASC, positive aspects of the program, and benefits from completing it. Participants valued the personalized approach, heart rate monitors, flexible scheduling, and a hybrid of in‐person and virtual sessions, reporting increased confidence, improved symptom management, and better mental health. Conclusion: A personalized respiratory physiotherapy program is feasible and may benefit individuals with PASC. Larger trials are needed to assess long‐term efficacy and scalability. Trial Registration: ClinicalTrials.gov identifier: NCT05040893
- 21 October 2025
- Published by Wiley in Health Science Reports
- Vol. 8 (10) , e71367
Open AccessIndividually Tailored Physiotherapy in Persons With Respiratory Symptoms Related to Post‐Acute Sequelae of COVID‐19: A Feasibility Study With Mixed Methods
Background and Aims: Post‐acute sequelae of COVID‐19 (PASC) commonly present with persistent respiratory symptoms, even in individuals with normal chest imaging and pulmonary function. Given the heterogeneity within this population, a personalized approach to respiratory physiotherapy could improve outcomes. The purpose of this study was to assess the feasibility and impact of a tailored respiratory physiotherapy program on health‐related quality of life (QoL), functional impairment, and patient‐reported outcome measures (PROMs) in individuals with persistent respiratory symptoms due to PASC. Methods: A single‐arm, open‐label trial was conducted with 13 adults diagnosed with PASC, recruited from Long COVID clinics in Calgary, Canada. Participants underwent an 8‐session personalized physiotherapy program, including education, breathing exercises, and strengthening. Feasibility was measured through recruitment, retention, and session completion rates. PROMs were collected at baseline and post‐intervention, and qualitative interviews explored participant perspectives. Results: The program was highly feasible, with 100% retention and a 99% completion rate. Significant improvements were observed in QoL, functional status (Post COVID‐19 Function Status scale), and self‐efficacy scores. The 6‐min walk test showed clinically meaningful improvements in three out of seven participants. Qualitative interviews ( n = 8) identified three main themes: struggles with PASC, positive aspects of the program, and benefits from completing it. Participants valued the personalized approach, heart rate monitors, flexible scheduling, and a hybrid of in‐person and virtual sessions, reporting increased confidence, improved symptom management, and better mental health. Conclusion: A personalized respiratory physiotherapy program is feasible and may benefit individuals with PASC. Larger trials are needed to assess long‐term efficacy and scalability. Trial Registration: ClinicalTrials.gov identifier: NCT05040893
- 1 June 2025
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 4 (6)
Gluten-Induced Hemoptysis: A Case Report of Lane–Hamilton Syndrome
- 1 June 2025
- Published by American College of Physicians in Annals of Internal Medicine: Clinical Cases
- Vol. 4 (6)
Gluten-Induced Hemoptysis: A Case Report of Lane–Hamilton Syndrome
- 6 August 2024
- Published by Taylor & Francis in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
- Vol. 8 (5) , 235-238
Barriers to multisite research in Canada: Experiences from a minimal risk COVID-19 study
- 6 August 2024
- Published by Taylor & Francis in Canadian Journal of Respiratory, Critical Care, and Sleep Medicine
- Vol. 8 (5) , 235-238
Barriers to multisite research in Canada: Experiences from a minimal risk COVID-19 study
- 1 April 2023
- Published by Springer Nature
- p. 697-717
Anti-tumor Necrosis Factor-α Antagonists and Tuberculosis
- 1 April 2023
- Published by Springer Nature
- p. 697-717
Anti-tumor Necrosis Factor-α Antagonists and Tuberculosis
- Open Access
- 1 December 2021
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-8
Evaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
Background: The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs. Methods: The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs. Results: There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs. Conclusion: Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.
- 1 December 2021
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 21 (1) , 1-8
Open AccessEvaluating hemoptysis hospitalizations among patients with bronchiectasis in the United States: a population-based cohort study
Background: The burden of hospitalizations and mortality for hemoptysis due to bronchiectasis is not well characterized. The primary outcome of our study was to evaluate in-hospital mortality in patients admitted with hemoptysis and bronchiectasis, as well as the rates of bronchial artery embolization, length of stay, and hospitalization costs. Methods: The authors queried the Nationwide Inpatient Sample (NIS) claims database for hospitalizations between 2016 and 2017 using the ICD-10-CM codes for hemoptysis and bronchiectasis in the United States. Multivariable regression was used to evaluate predictors of in-hospital mortality, embolization, length of stay, and hospital costs. Results: There were 8240 hospitalizations (weighted) for hemoptysis in the United States from 2016 to 2017. The overall in-hospital mortality was 4.5%, but higher in males compared to females. Predictors of in-hospital mortality included undergoing three or more procedures, age, and congestive heart failure. Bronchial artery embolization (BAE) was utilized during 2.1% of hospitalizations and was more frequently used in those with nontuberculous mycobacteria and aspergillus infections, but not pseudomonal infections. The mean length of stay was 6 days and the median hospitalization cost per patient was USD $9,610. Having comorbidities and procedures was significantly associated with increased length of stay and costs. Conclusion: Hemoptysis is a frequent indication for hospitalization among the bronchiectasis population. In-hospital death occurred in approximately 4.5% of hospitalizations. The effectiveness of BAE in treating and preventing recurrent hemoptysis from bronchiectasis needs to be explored.
- Open Access
- 9 September 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Fewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
Refugees are at increased risk of developing tuberculosis (TB) soon after resettlement. Targeting high-risk populations for latent tuberculosis infection (LTBI) screening and treatment is an important measure towards eliminating TB in low incidence countries, however, there are low rates of screening and treatment completion in the LTBI cascade of care. The authors hypothesized that an interferon-gamma release assay (IGRA) screening strategy would lead to a higher proportion of refugees completing LTBI screening and treatment, compared to sequential screening with tuberculin skin test (TST) and confirmatory IGRA. This retrospective cohort study included eligible refugees screened with a sequential strategy versus a solo-IGRA strategy at different time periods from a centralized refugee clinic. The primary outcome was the proportion completing LTBI screening in each cohort. A total of 471 subjects were included (240 in sequential screening, 231 in solo-IGRA screening). 54% of refugees completed LTBI screening with sequential testing, compared to 85% of those screened with a solo-IGRA. Time to completing screening was also shorter in the solo-QFT group (difference 16.5 days, p < 0.01, 95% confidence interval 9.3, 23.7). There was a higher incidence of LTBI diagnosis in the solo-IGRA group (41 versus 20, p = 0.002). Screening completion was predicted by solo-IGRA screening (aOR 3.74, 95% confidence interval 2.30, 6.09; p < 0.001) and if refugees were privately-sponsored (aOR 2.81, 95% confidence interval 1.53, 5.15; p = 0.001). Treatment completion rates did not differ between groups. This study has identified fewer dropouts in the LTBI cascade of care if a solo-IGRA strategy is used for screening. An IGRA should be strongly considered as the screening method for refugees arriving in low-incidence settings if resources are available.
- 9 September 2021
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 21 (1) , 1-8
Open AccessFewer losses in the cascade of care for latent tuberculosis with solo interferon-gamma release assay screening compared to sequential screening
Refugees are at increased risk of developing tuberculosis (TB) soon after resettlement. Targeting high-risk populations for latent tuberculosis infection (LTBI) screening and treatment is an important measure towards eliminating TB in low incidence countries, however, there are low rates of screening and treatment completion in the LTBI cascade of care. The authors hypothesized that an interferon-gamma release assay (IGRA) screening strategy would lead to a higher proportion of refugees completing LTBI screening and treatment, compared to sequential screening with tuberculin skin test (TST) and confirmatory IGRA. This retrospective cohort study included eligible refugees screened with a sequential strategy versus a solo-IGRA strategy at different time periods from a centralized refugee clinic. The primary outcome was the proportion completing LTBI screening in each cohort. A total of 471 subjects were included (240 in sequential screening, 231 in solo-IGRA screening). 54% of refugees completed LTBI screening with sequential testing, compared to 85% of those screened with a solo-IGRA. Time to completing screening was also shorter in the solo-QFT group (difference 16.5 days, p < 0.01, 95% confidence interval 9.3, 23.7). There was a higher incidence of LTBI diagnosis in the solo-IGRA group (41 versus 20, p = 0.002). Screening completion was predicted by solo-IGRA screening (aOR 3.74, 95% confidence interval 2.30, 6.09; p < 0.001) and if refugees were privately-sponsored (aOR 2.81, 95% confidence interval 1.53, 5.15; p = 0.001). Treatment completion rates did not differ between groups. This study has identified fewer dropouts in the LTBI cascade of care if a solo-IGRA strategy is used for screening. An IGRA should be strongly considered as the screening method for refugees arriving in low-incidence settings if resources are available.
- Open Access
- 4 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246113
Patient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda
A 12-dose weekly regimen of rifapentine plus isoniazid (3HP) is recommended for the prevention of active tuberculosis (TB); however, it is unclear whether 3HP should be provided by directly observed therapy (DOT) or self-administered therapy (SAT). In addition, the introduction of patient informed choice between delivery modalities may have a positive impact on factors leading to treatment completion. The authors randomized 252 participants with HIV to a hypothetical scenario of providing preventive therapy by either DOT or an informed choice between DOT and SAT. Out of 104 participants who were randomized to a choice between DOT and SAT, 103 chose therapy by SAT. Participants rated their level of confidence and intention to complete therapy. Compared to those assigned to the DOT scenario, patients assigned to the choice scenario expressed greater confidence and intention to complete preventive therapy. Convenience and travel required to complete 3HP therapy were important factors in deciding between delivery modalities. Those assigned to DOT identified more barriers to completing therapy than those given a choice. Empowering patients to make informed decisions about how they receive TB preventive therapy may improve completion rates.
- 4 February 2021
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 16 (2) , e0246113
Open AccessPatient choice improves self-efficacy and intention to complete tuberculosis preventive therapy in a routine HIV program setting in Uganda
A 12-dose weekly regimen of rifapentine plus isoniazid (3HP) is recommended for the prevention of active tuberculosis (TB); however, it is unclear whether 3HP should be provided by directly observed therapy (DOT) or self-administered therapy (SAT). In addition, the introduction of patient informed choice between delivery modalities may have a positive impact on factors leading to treatment completion. The authors randomized 252 participants with HIV to a hypothetical scenario of providing preventive therapy by either DOT or an informed choice between DOT and SAT. Out of 104 participants who were randomized to a choice between DOT and SAT, 103 chose therapy by SAT. Participants rated their level of confidence and intention to complete therapy. Compared to those assigned to the DOT scenario, patients assigned to the choice scenario expressed greater confidence and intention to complete preventive therapy. Convenience and travel required to complete 3HP therapy were important factors in deciding between delivery modalities. Those assigned to DOT identified more barriers to completing therapy than those given a choice. Empowering patients to make informed decisions about how they receive TB preventive therapy may improve completion rates.
- 1 May 2019
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 263, 14-19
Transthoracic sonographic assessment of B-line scores during ascent to altitude among healthy trekkers
- 1 May 2019
- Published by Elsevier in Respiratory Physiology & Neurobiology
- Vol. 263, 14-19
Transthoracic sonographic assessment of B-line scores during ascent to altitude among healthy trekkers